Survival Analysis for Patients with ALK Rearrangement‐Positive Non‐Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401

LESSONS LEARNED: Alectinib confers a pronounced survival benefit in patients with ALK rearrangement‐positive non‐small cell lung cancer and a poor performance status. Survival benefit of alectinib for patients with a poor performance status was consistent regardless of the presence of central nervou...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Iwama, Eiji, Goto, Yasushi, Murakami, Haruyasu, Tsumura, Shinsuke, Sakashita, Hiroyuki, Mori, Yoshiaki, Nakagaki, Noriaki, Fujita, Yuka, Seike, Masahiro, Bessho, Akihiro, Ono, Manabu, Nishitsuji, Masaru, Akamatsu, Hiroaki, Morinaga, Ryotaro, Akagi, Takanori, Shimose, Takayuki, Tokunaga, Shoji, Yamamoto, Nobuyuki, Nakanishi, Yoichi, Sugio, Kenji, Okamoto, Isamu
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2019
Soggetti:
Clinical Trial Results
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160311/
https://ncbi.nlm.nih.gov/pubmed/32297438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0728
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi